doi: 10.1001/jamadermatol.2022.5146.
Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea
Affiliations
- PMID: 36449277
- DOI: 10.1001/jamadermatol.2022.5146
Item in Clipboard
Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea
JAMA Dermatol.
.
No abstract available
Plain language summary
This case report describes a 78-year old woman with a stage IIA BRAF wild-type melanoma on the left leg who experienced a grade 2 vitiligo, a marked skin thickening, and painful swelling of the limbs.
Similar articles
-
Nivolumab-induced plaque morphea in a malign melanoma patient.J Cosmet Dermatol. 2021 Aug;20(8):2645-2647. doi: 10.1111/jocd.13914. Epub 2020 Dec 28. J Cosmet Dermatol. 2021. PMID: 33355973
-
Nivolumab induced morphea.G Ital Dermatol Venereol. 2020 Oct;155(5):701-702. doi: 10.23736/S0392-0488.18.06118-7. Epub 2018 Oct 3. G Ital Dermatol Venereol. 2020. PMID: 30295447 No abstract available.
-
Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.Eur J Dermatol. 2021 Dec 1;31(6):844-846. doi: 10.1684/ejd.2021.4181. Eur J Dermatol. 2021. PMID: 34911674 Free PMC article. No abstract available.
-
Morphea associated with the use of adalimumab: a case report and review of the literature.Mod Rheumatol. 2012 Aug;22(4):602-4. doi: 10.1007/s10165-011-0550-4. Epub 2011 Nov 18. Mod Rheumatol. 2012. PMID: 22095405 Review.
-
Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.Melanoma Res. 2021 Feb 1;31(1):98-100. doi: 10.1097/CMR.0000000000000713. Melanoma Res. 2021. PMID: 33323722 Review.
Cited by
-
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.Am J Clin Dermatol. 2024 Jul;25(4):595-607. doi: 10.1007/s40257-024-00866-z. Epub 2024 May 20. Am J Clin Dermatol. 2024. PMID: 38767827 Review.
-
Recent Advances in Treatment of Systemic Sclerosis and Morphea.Am J Clin Dermatol. 2024 Mar;25(2):213-226. doi: 10.1007/s40257-023-00831-2. Epub 2023 Dec 12. Am J Clin Dermatol. 2024. PMID: 38087156 Review.
-
Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel). 2023 Nov 15;16(11):1610. doi: 10.3390/ph16111610. Pharmaceuticals (Basel). 2023. PMID: 38004475 Free PMC article. Review.
-
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma.Cancers (Basel). 2023 Mar 31;15(7):2084. doi: 10.3390/cancers15072084. Cancers (Basel). 2023. PMID: 37046745 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
